Singapore rhabdomyosarcoma (RMS) experience: shall we change our practice?

Lele Aung1, Tin Aung Soe, Kenneth Te Chang

  • 1Division of Paediatric Haematology-Oncology, KK Women's and Children's Hospital, Singapore.

Insights

Outcomes for children with rhabdomyosarcoma (RMS) in Singapore show significant differences based on risk group. Low-risk patients have good survival, while high-risk patients require radiation therapy for better results.

Area of Science:

  • Pediatric Oncology
  • Cancer Research
  • Clinical Outcomes

Background:

  • Rhabdomyosarcoma (RMS) is a significant childhood cancer in Singapore.
  • Data on the prognosis of pediatric RMS patients in Singapore was previously limited.

Purpose of the Study:

  • To investigate the outcomes of children diagnosed with rhabdomyosarcoma in Singapore.
  • To analyze survival rates based on risk stratification and treatment protocols.

Main Methods:

  • A retrospective study of 50 pediatric RMS patients treated between 1993 and 2010.
  • Patients received treatment according to Intergroup Rhabdomyosarcoma Study Group (IRSG) or Société Internationale Pediatrique D'Oncologie (SIOP) regimens.
  • Risk stratification used the IRSG classification system.

Main Results:

  • Overall 5-year event-free survival (EFS) varied significantly by risk group: 81.3% for low-risk (LR), 61.4% for intermediate-risk (IR), and 25.0% for high-risk (HR).
  • High-risk patients had a higher rate of relapse and mortality.
  • Treatment outcomes showed differences between SIOP and IRSG protocols, particularly for intermediate and high-risk groups.

Conclusions:

  • Radiation therapy is crucial for higher-risk RMS classifications.
  • Improving outcomes requires a cooperative approach, emphasizing multidisciplinary collaboration and standardized protocols.
  • Enhanced data collection and communication are vital for optimizing pediatric RMS care in Singapore.
Abstract